I'm loving the synergy between Asterias, BioTime and Geron.
When Asterias succeeds watch out--so few shares, AND then BioTime succeeds and my warrants get more valuable(BioTime owns 21million of AST's 32 million share float) and then Geron succeeds--they receive royalties from Asterias on stem cell products and my Geron shares go up. Cool.
Great news for Asterias AND for Biotime.
Of Asterias's 32 million shares, Biotime owns 21 million! Is that right?!
Not many shares to go around when this gets rolling. And spinal chord injury is not like cancer--when one gets results, they are visible to everyone. Good luck to all longs.
What 5-10 million?
Most are owned by parent company, BioTime, and by old Geron shareholders. This could get interesting!
I like the way this is working out for long-time GERN holders--better than I thought it would be. Got a bunch of Asterias, got a bunch of BTX warrants--when Asterias makes progress I get rewarded times three. Go Asterias! I'm buying some more.
As we shared a few weeks ago, fourth-quarter results surpassed our expectations, with revenue of $592 million, an increase of 15% over the prior-year period, and our 17th consecutive quarter of sequential growth.
During the quarter, we witnessed robust trends across the business, including year-over-year total sequencing growth of 19%, and 30% shipment growth to clinical and translational customers. Demand from clinical oncology customers contributed to the strong Q4 result, with approximately 40% growth compared to the prior-year quarter.
We're very pleased with the commercial uptake of the TST 15 product and the TST 170 development program remains on track. These panels are based on initial standards defined by the Actionable Genome Consortium and were developed to drive adoption of the NGS in the translational market and by pharma partners in their clinical trials. Encouragingly, we recently announced that Amgen will be utilizing the IUO version of TST 15 as part of new oncology development program and we're in discussions with other potential pharma partners, as well.
In early January, we formed GRAIL, a new Company focused on the cancer screening market. We're currently working to transfer our ctDNA programs, the MSK partnership and the employees working on these projects to GRAIL. We're in the late stages of recruiting a CEO and have identified a potential lab and office space in the Bay area.
We've begun work on the detailed planning necessary to embark on a large scale clinical trial in 2017, with a goal of demonstrating a stage shift in diagnosis. In our reproductive and genetic health business, we saw strong adoption of both our IVF and NIPT products in the fourth quarter. Sales of our preimplantation genetic screening, or PGS products, increased close to 25% compared to the fourth quarter of 2014. Further, we completed enrollment in the STAR trial ahead of schedule, which will measure the impact of PGS and embryo morphology on IVF success rates.
Parkinson's, Alzheimer's, and Huntington's--Prana's MPAC's seem to be likely to do alot of good in the world.
Personally, if one is a conspiracy theorist I'd be suspecting Fartstain's crew of sneaking the placebo outlier into Prana's trial.
FAR more reasons to suspect that crew of evil behavior. They have so many lawsuits pending against them one would have to take a ticket and stand in line. JMHO, of course.
If I do not tender my shares (and I will not), if Astellas succeeds anyway and buys OCATA, will I still receive $8.50 for my shares somewhere down the road?
I agree, bob. Bought some yesterday and the day before. Will probably buy some more later today. Watch the science.
I don't know when the market will turn around, but I'm seizing the moment to buy a little more stock when I can.
There are many disingenuous people recommending selling now during the downturn. That's NOT how to make money in the stock market (and they know it). GLTA longs. Things will turn around. This one is a winner in MHO.
Yes, thank you biotime (and geron, too).
I don't know when the market will turn around but I'm seizing the moment to buy a little stock when I can. Many disingenuous people recommending selling during the weakness. That's NOT how to make money in the market (and they know it).
So for every 100 warrants I am now entitled to purchase 110 shares and these are exercisable at $4.55 per share. GREAT!
Inch by inch, row by row, going to make my garden grow.
I agree. Thank you Geron and Biotime.
I have to believe that you are right about this only applying to warrants purchased before the spin-off. Anyone know for sure?